The Drug Debate: Data Exclusivity is the New Way to Delay Generics

Authors

Srividhya Ragavan, Texas A&M University School of LawFollow

Document Type

Article

Publication Date

3-2018

Journal Title

Connecticut Law Review Online

ISSN

0010-6151

Abstract

The article discusses the protection regime for clinical trial data internationally and outlines the applicable protection regime. In doing so, this article outlines how the data exclusivity regime can operate in parallel with the patent regime to add a layer of protection for the data. Such protection operates at a regulatory level to delay the entry of generic medications. Internationally, the data exclusivity regime, which has become an important contemporary tool in trade negotiations with poorer nations, works to detrimentally affect access to medication

First Page

1

Last Page

14

Num Pages

14

Volume Number

50

Issue Number

2

Publisher

University of Connecticut School of Law

Recommended Citation

Srividhya Ragavan, The Drug Debate: Data Exclusivity is the New Way to Delay Generics, 50 Conn. L. Rev. Online 1 (2018).
Available at: https://scholarship.law.tamu.edu/facscholar/1184

File Type

PDF